PROKIDNEY CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.81 USD | +7.66% |
|
+27.73% | +57.87% |
| May. 10 | ProKidney Q1 Loss Unchanged From Year Earlier | MT |
| May. 10 | ProKidney Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 180M |
|---|---|---|---|---|---|
| Net income 2024 * | -157M | Net income 2025 * | -40M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 152M | Net cash position 2025 * | 295M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.19
x | P/E ratio 2025 * |
-3.61
x | Employees | 163 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.55% |
More Fundamentals
* Assessed data
More news
Latest transcript on ProKidney Corp.
More recommendations
More press releases
| 1 day | +7.66% | ||
| 1 week | +27.73% | ||
| Current month | +36.08% | ||
| 1 month | +93.79% | ||
| 3 months | +130.33% | ||
| 6 months | +75.62% | ||
| Current year | +57.87% |
1 week
2.11
2.86
1 month
1.603.37
Current year
1.183.37
1 year
1.1213.51
3 years
1.1214.19
5 years
1.1214.19
10 years
1.1214.19
| Managers | Title | Age | Since |
|---|---|---|---|
Bruce Culleton
CEO | Chief Executive Officer | 57 | 23-07-16 |
James Coulston
DFI | Director of Finance/CFO | 48 | 21-12-31 |
Joseph Stavas
CTO | Chief Tech/Sci/R&D Officer | 69 | 19-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Doyle
BRD | Director/Board Member | 61 | 21-12-31 |
Brian Pereira
BRD | Director/Board Member | 65 | 21-12-31 |
John Maraganore
BRD | Director/Board Member | 60 | 22-08-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.63% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 2.81 | +7.66% | 459,739 |
| 24-05-09 | 2.61 | +7.85% | 505,430 |
| 24-05-08 | 2.42 | +1.26% | 297,644 |
| 24-05-07 | 2.39 | +6.70% | 384,987 |
| 24-05-06 | 2.24 | +1.82% | 294,364 |
End-of-day quote Nasdaq, May 09, 2024
More quotes
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patientâs own cells isolated from the patient intended for treatment. The Companyâs lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patientâs diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patientâs own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participantâs own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Calendar
2024-05-13
- BofA Securities Health Care Conference
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.81
USD
Average target price
4.2
USD
Spread / Average Target
+49.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +57.87% | 180M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- PROK Stock
